ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study
Portfolio Pulse from
Alector's stock has dropped following the failure of its phase II INVOKE-2 study, which was evaluating the drug AL002 for slowing the progression of early Alzheimer's disease. The study did not meet its primary goal.
November 27, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Alector's stock has fallen due to the failure of its phase II INVOKE-2 study for the Alzheimer's drug AL002, which did not meet its primary endpoint.
The failure of the phase II study is a significant setback for Alector, as it impacts the potential future revenue from AL002. This negative outcome is likely to affect investor sentiment and lead to a short-term decline in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100